V Rosato1, A Zucchetto2, C Bosetti1, L Dal Maso3, M Montella4, C Pelucchi1, E Negri1, S Franceschi5, C La Vecchia6. 1. Department of Epidemiology, Istituto di Ricerche Farmacologiche 'Mario Negri', Milan. 2. Unit of Epidemiology and Biostatistics, Centro di Riferimento Oncologico, Aviano. 3. Unit of Epidemiology and Biostatistics, Centro di Riferimento Oncologico, Aviano; Department of Occupational Medicine, Sezione di Statistica Medica e Biometria 'Giulio A. Maccacaro', Università degli Studi di Milano, Milan, Italy. 4. Unit of Epidemiology, Istituto Nazionale Tumori 'Fondazione G. Pascale', Napoli, Italy. 5. International Agency for Research on Cancer, Lyon, France. 6. Department of Epidemiology, Istituto di Ricerche Farmacologiche 'Mario Negri', Milan; Department of Occupational Medicine, Sezione di Statistica Medica e Biometria 'Giulio A. Maccacaro', Università degli Studi di Milano, Milan, Italy. Electronic address: Carlo.LaVecchia@marionegri.it.
Abstract
BACKGROUND: Various studies reported direct associations between endometrial cancer risk and individual components of the metabolic syndrome (MetS), i.e. obesity, diabetes, hypertension, and dyslipidemia, but only a few epidemiological studies considered the association with MetS overall. METHODS: We analyzed data from a case-control study including 454 women with incident endometrial cancer and 798 controls admitted to the same hospitals as cases for acute conditions. Different definitions of MetS were considered, including a combination of self-reported history of diabetes, drug-treated hypertension, drug-treated hyperlipidemia, and various measures of (central) obesity. Odds ratios (ORs) were computed from unconditional logistic regression models, adjusted for major confounding factors. RESULTS: The multivariate ORs of endometrial cancer were 2.18 for type 2 diabetes, 1.77 for hypertension, 1.20 for hyperlipidemia, between 1.62 and 2.23 for various definitions of central obesity, and 3.83 for women with a body mass index (BMI) >30 kg/m(2). The risk of endometrial cancer was significantly increased for subjects with MetS, the ORs ranging between 1.67 and 2.77 when waist circumference was included in MetS definition, and 8.40 when BMI was considered instead. CONCLUSIONS: This study indicates a direct association between various MetS components, besides overweight, with the risk of endometrial cancer.
BACKGROUND: Various studies reported direct associations between endometrial cancer risk and individual components of the metabolic syndrome (MetS), i.e. obesity, diabetes, hypertension, and dyslipidemia, but only a few epidemiological studies considered the association with MetS overall. METHODS: We analyzed data from a case-control study including 454 women with incident endometrial cancer and 798 controls admitted to the same hospitals as cases for acute conditions. Different definitions of MetS were considered, including a combination of self-reported history of diabetes, drug-treated hypertension, drug-treated hyperlipidemia, and various measures of (central) obesity. Odds ratios (ORs) were computed from unconditional logistic regression models, adjusted for major confounding factors. RESULTS: The multivariate ORs of endometrial cancer were 2.18 for type 2 diabetes, 1.77 for hypertension, 1.20 for hyperlipidemia, between 1.62 and 2.23 for various definitions of central obesity, and 3.83 for women with a body mass index (BMI) >30 kg/m(2). The risk of endometrial cancer was significantly increased for subjects with MetS, the ORs ranging between 1.67 and 2.77 when waist circumference was included in MetS definition, and 8.40 when BMI was considered instead. CONCLUSIONS: This study indicates a direct association between various MetS components, besides overweight, with the risk of endometrial cancer.
Authors: Jennifer Prescott; Ying Bao; Akila N Viswanathan; Edward L Giovannucci; Susan E Hankinson; Immaculata De Vivo Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-05-23 Impact factor: 4.254
Authors: James N Mubiru; Magdalena Garcia-Forey; Paul B Higgins; Peggah Hemmat; Nicole E Cavazos; Edward J Dick; Michael A Owston; Cassondra A Bauer; Robert E Shade; Anthony G Comuzzie; Jeffrey Rogers Journal: J Med Primatol Date: 2011-08-03 Impact factor: 0.667
Authors: Britton Trabert; Nicolas Wentzensen; Ashley S Felix; Hannah P Yang; Mark E Sherman; Louise A Brinton Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-01 Impact factor: 4.254
Authors: Nicolae Bacalbasa; Camelia Diaconu; Laura Iliescu; Cornel Savu; Carmen Savu; Cristian Balalau; Mihai Dimitriu; Alexandru Filipescu; Ovidiu Gabriel Bratu; Adrian Neacsu; Dragos Cretoiu; Ioana Halmaciu; Irina Balescu Journal: In Vivo Date: 2020 Sep-Oct Impact factor: 2.155